Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Investigator-Initiated Exploratory Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Injection BBM-C101 in Subjects With HPV16/18 Infection

NCT07714577 is registered in ClinicalTrials.gov with Tianjin First Central Hospital as lead sponsor.

NCT NCT07714577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07714577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Investigator-Initiated Exploratory Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Injection BBM-C101 in Subjects With HPV16/18 Infection
Lead sponsor
Tianjin First Central Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 30, 2026
Completion date
August 1, 2031
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hpv16/18 positive